Mitsubishi Tanabe Fending Off Inroads from Biosimilars through Add’l Indications for Remicade

Katsuaki Kitayama, Deputy Manager of Sales & Marketing Division Mitsubishi Tanabe Pharma plans to seek additional indications in fields including inflammatory bowel disease (IBD) for its anti-TNFα antibody drug Remicade (infliximab) in order to minimize inroads by biosimilars and NHI...read more